Studies have shown that PD-L1 expression is a predictor of pathologic complete response (pCR) for neoadjuvant chemotherapy in breast cancer patients [4, 5], and effective response rates correlate with the immune checkpoint inhibitor treatment [6]. Here, CD274 is linked to breast carcinoma.